Navigation Links
Bionovo, Inc. to Announce Second Quarter Fiscal Year 2009 Financial Results on Monday, August 10, 2009
Date:8/3/2009

EMERYVILLE, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced today that it will release financial results for the second quarter of fiscal year 2009 ended June 30, 2009 on Monday, August 10, 2009. The Company will conduct a conference call and web cast to review the financial results on Monday, August 10, 2009 at 5:00 p.m. ET.

Interested parties can access the call by dialing (800) 860-2442 or (412) 858-4600, or can listen via a live Internet web cast, which can be found at http://bionovo.com/investors/events. A replay of the call is available via web cast at http://bionovo.com/investors/events for 30 days or by playback at (877) 344-7549 or (412) 317-0088, conference code 432836, through August 13, 2009.

About Bionovo, Inc.

Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com. BNVI-F


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Human Genome Sciences Announces Closing of Public Offering
2. International Milk Genomics & Human Health Symposium Speaker Program Announced
3. Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
4. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
5. Yongye International Announces Branded Store Network Increases Over 40% to 5,000 Stores
6. Hoya Announces First Quarter Financial Results for FY2010
7. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
8. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
9. Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call
10. IIVS Announces Initiation by EPA of a Pilot Program to Evaluate Non-Animal Eye-Irritation Methods
11. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , January 20, 2017 ... is one of leading causes of death worldwide. There ... the number of cancer related deaths increased gradually over ... in incidence rate of various cancers continues to drive ... research report by Global Market Insights, Inc. cancer biological ...
(Date:1/19/2017)... Research Future has a half cooked research report on Global Liquid ... and expected to reach USD 450 Million by the end of ... ... assessed as a swiftly growing market and expected that the market ... There has been a tremendous growth in the prevalence of cancer ...
(Date:1/19/2017)... and Markets ... addition of the "Implantable Biomaterials Market Analysis & ... to their offering. Report Highlights: ... current and future market trends to identify the investment opportunities ... numbers Key market trends across the business segments, Regions ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 /PRNewswire/ ... a privately-held immunotherapeutics company targeting infectious diseases, announced ... the merger of PharmAthene and Altimmune in an ... Fund, HealthCap, Truffle Capital and Redmont Capital. The ... immunotherapeutics company with four clinical stage and one ...
Breaking Biology Technology:
(Date:1/3/2017)... VEGAS , Jan. 3, 2017 Onitor, ... the introduction of Onitor Track, an innovative biometric data-driven ... men, showcasing this month at the 2017 Consumer Electronics ... In the U.S., the World Health ... more than two-thirds of adults who are overweight or ...
(Date:12/20/2016)... 20, 2016   Valencell , the leading ... STMicroelectronics (NYSE: STM), a global semiconductor leader ... announced today the launch of a new, highly ... that includes ST,s compact SensorTile turnkey ... biometric sensor system. Together, SensorTile and Benchmark deliver ...
(Date:12/16/2016)... The global wearable medical device market, in terms of ... USD 5.31 billion in 2016, at a CAGR of 18.0% during ... ... in medical devices, launch of a growing number of smartphone-based healthcare ... healthcare providers, and increasing focus on physical fitness. ...
Breaking Biology News(10 mins):